BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025.
Galecto Reports First Quarter 2025 Operating and Financial Results
Seeking Alpha / 37 minutes from now 1 Views
Comments